The Wall Street Journal examines billing codes used by uBiome.
Business Insider reports that uBiome halted the sale and testing of its SmartJane and SmartGut tests.
The moves come in the wake of an FBI search of the company's San Francisco office as part of an investigation into its billing practices.
The Wall Street Journal reports that the Federal Bureau of Investigation has searched uBiome's office as part of an inquiry into its billing practices.
The partners aim to determine whether the microbiome can be used to predict patient responses to certain inflammatory bowel disease therapies.
The company, which employs 300 people, axed 30 jobs in the US and 25 jobs from its overseas operations as it refocuses on therapeutic development.
The financing round will support uBiome's ongoing efforts to commercialize its clinical microbiome analysis, sexually-transmitted disease, and gut wellness tests.
The sequencing-based, laboratory-developed test, called SmartJane, contains the first commercially available vaginal microbiome assay.
The collaborators plan to collect samples that will allow them insight into participants' microbiomes in order to understand disease mechanisms over time.
The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.
Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.
NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.
In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.